The global asthma treatment market was valued at USD 18.08 billion in 2019 and is expected to grow to USD 32.81 billion by 2032, registering a CAGR of 4.6% over the forecast period. In 2019, North America held a dominant share of 51.99% in the global market.
The asthma treatment market is experiencing steady growth driven by the increasing prevalence of asthma worldwide and advancements in therapeutic options. The market includes a variety of treatments designed to manage symptoms and improve patient quality of life, ranging from inhalers to biologic therapies. Growing awareness, technological innovations, and expanding healthcare infrastructure across regions are further fueling market expansion. Despite challenges such as high treatment costs and patient adherence issues, ongoing research and development efforts continue to introduce more effective and convenient treatment options, supporting the overall growth of the asthma treatment market.
Continue reading for more details:
https://www.fortunebusinessinsights.com/industry-reports/asthma-treatment-market-101039
Global Asthma Treatment Market – Key Takeaways
Market Size & Forecast:
2019 Value: USD 18.08 billion
2032 Forecast Value: USD 32.81 billion
CAGR: 4.6% (2019–2032)
Market Share:
Regional Leadership: North America accounted for 51.99% of the global market in 2019, supported by a high asthma prevalence, strong patient awareness, higher healthcare spending, and the presence of leading biopharmaceutical companies.
By Treatment Type: Long-term control medications held the largest share in 2019, reflecting the chronic nature of asthma and the broad adoption of products such as Advair, Symbicort, and Qvar. These treatments ensure sustained symptom management and better patient outcomes.
Key Country Highlights:
Japan: Market growth is driven by an aging population, rising awareness of asthma management, and government reimbursement policies for approved therapies.
United States: Maintains leadership in drug development and approvals, bolstered by strong sales of Symbicort and Advair, heightened R&D efforts, and rapid adoption of generics post-COVID-19.
China: Witnesses strong demand growth due to higher diagnosis rates, improved access to inhalation therapies such as Pulmicort, and expanding healthcare infrastructure in urban and semi-urban areas.
Europe: Growth is propelled by asthma being the most common chronic disease among children, alongside initiatives promoting early diagnosis, biosimilar adoption, and universal health coverage for asthma treatments.
Market Segmentation
By Treatment Type: inhaled corticosteroids, long-acting beta‑agonists, combination therapies, biologics, and supportive care represent major segments in the Asthma Treatment Market.
By Patient Age Group: pediatric, adolescent, adult, and geriatric segments are delineated in the Asthma Treatment Market.
By Route of Administration: inhalers (metered‑dose, dry powder), oral tablets, nebulizers, and injectable biologics make up the Asthma Treatment Market segmentation.
By End‑User: hospitals, specialty clinics, home care settings, and outpatient centers are key channels in the Asthma Treatment Market.
By Geography: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa are the regional segments in the Asthma Treatment Market.
List Of Key Companies Profiled:
AstraZeneca
GlaxoSmithKline plc
Teva Pharmaceutical Industries Ltd.
Merck & Co., Inc.
Mylan N.V.
Boehringer Ingelheim International GmbH
Regeneron
Sanofi
Genentech, Inc. (F. Hoffmann-La Roche Ltd)
Novartis AG
Sumitomo Dainippon Pharma Co., Ltd.
Others
Market Growth
The Asthma Treatment Market is experiencing steady growth driven by rising prevalence of asthma globally.
Expansion in healthcare access and increasing adoption of inhalers and biologic therapies are fueling the Asthma Treatment Market.
Ongoing research and regulatory approvals for novel therapies are boosting momentum in the Asthma Treatment Market.
Growing awareness and patient education programs contribute to expanding the Asthma Treatment Market.
Emerging markets with improving healthcare infrastructure are accelerating growth in the Asthma Treatment Market.
Restraining Factors
High cost of advanced biologic therapies limits adoption within the Asthma Treatment Market.
Limited reimbursement in low‑income countries restricts access and hampers Asthma Treatment Market expansion.
Safety concerns and side effects related to long‑term steroid use act as restraining factors in the Asthma Treatment Market.
Regulatory challenges and lengthy approval processes may delay product launches in the Asthma Treatment Market.
Regional Analysis
North America: leads the Asthma Treatment Market due to strong healthcare infrastructure and high usage of advanced therapies.
Europe: significant share in the Asthma Treatment Market, with growing emphasis on combination inhalers and biologicals.
Asia Pacific: rapid expansion of the Asthma Treatment Market driven by urbanization and rising diagnosis rates.
Latin America: moderate growth in the Asthma Treatment Market, with expanding insurance coverage and awareness initiatives.
Middle East & Africa: emerging Asthma Treatment Market opportunities fueled by improving healthcare access and increasing patient education.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower,
Baner - Mahalunge Road,
Baner, Pune-411045, Maharashtra, India.
Phone: U.S.: +1 424 253 0390
U.K.: +44 2071 939123
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com